2022-03-30
Dx&Vx, Hanyang Institute of Bioscience and Biotechnology to co-develop new drugs
Dx&Vx signed a memorandum of understanding on industry-university-research cooperation with the Hanyang Institute of Bioscience and Biotechnology (HY-IBB) on Tuesday.
Under the accord, Dx&Vx and HY-IBB will jointly operate NGS (Next Generation Sequencing) equipment of the genome core and collaborate to develop mRNA-based therapeutics, vaccines, and next-generation biopharmaceuticals.
Dx&Vx will also participate in the research on the next-generation mRNA vaccine structure now underway at HY-IBB.
Also, the two parties plan to produce big genome data and build a database with Professor Nam Jin-woo of the department of life sciences at Hanyang University.
“To build an mRNA platform, we plan to start validation studies at the cellular level, including the recently promoted immune profile, by analyzing expression through validation using sequencing and diversification of structural models through genome analysis equipment,” a company official said. “Dx&Vx CEO Park Sang-tae and research center head Park Sang-jin will participate in advancing the project.”
Dx&Vx expects to expand into business such as commercialization of original technology by linking Hanyang University Medical Center’s HY-SPARK program with HY-IBB.
The company is discussing the use of NovaSeq, Dx&Vx’s next-generation high-performance analysis platform, and NextSeq, the company's ultra-high-speed sequencing analyzer in the research lab, to support research.
“With the full support of the Hanyang University Foundation, we are delighted to collaborate on next-generation biotechnology research with HY-IBB, which has excellent faculty,” Dx&Vx CEO Park said. “We expect to expand opportunities for technological cooperation by collaborating with research groups that conduct high-level research based on various genomic fields and clinical data.”
Dx&Vx also plans to play a leading role in mRNA-based therapeutics and vaccines, next-generation biopharmaceuticals, and digital health care projects promoted by its affiliate, Coree Group, through global industry-university cooperation.
출처 : KBR
URL : http://www.koreabiomed.com/news/articleView.html?idxno=13397
Under the accord, Dx&Vx and HY-IBB will jointly operate NGS (Next Generation Sequencing) equipment of the genome core and collaborate to develop mRNA-based therapeutics, vaccines, and next-generation biopharmaceuticals.Dx&Vx will also participate in the research on the next-generation mRNA vaccine structure now underway at HY-IBB.
Also, the two parties plan to produce big genome data and build a database with Professor Nam Jin-woo of the department of life sciences at Hanyang University.
“To build an mRNA platform, we plan to start validation studies at the cellular level, including the recently promoted immune profile, by analyzing expression through validation using sequencing and diversification of structural models through genome analysis equipment,” a company official said. “Dx&Vx CEO Park Sang-tae and research center head Park Sang-jin will participate in advancing the project.”
Dx&Vx expects to expand into business such as commercialization of original technology by linking Hanyang University Medical Center’s HY-SPARK program with HY-IBB.
The company is discussing the use of NovaSeq, Dx&Vx’s next-generation high-performance analysis platform, and NextSeq, the company's ultra-high-speed sequencing analyzer in the research lab, to support research.
“With the full support of the Hanyang University Foundation, we are delighted to collaborate on next-generation biotechnology research with HY-IBB, which has excellent faculty,” Dx&Vx CEO Park said. “We expect to expand opportunities for technological cooperation by collaborating with research groups that conduct high-level research based on various genomic fields and clinical data.”
Dx&Vx also plans to play a leading role in mRNA-based therapeutics and vaccines, next-generation biopharmaceuticals, and digital health care projects promoted by its affiliate, Coree Group, through global industry-university cooperation.
URL : http://www.koreabiomed.com/news/articleView.html?idxno=13397